Compare SFBS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBS | OGN |
|---|---|---|
| Founded | 2005 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | 2014 | 2020 |
| Metric | SFBS | OGN |
|---|---|---|
| Price | $38.69 | $13.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $46.33 | $11.25 |
| AVG Volume (30 Days) | 590.0K | ★ 1.9M |
| Earning Date | 10-19-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.93% | 0.58% |
| EPS Growth | ★ 21.63 | N/A |
| EPS | ★ 3.09 | 0.95 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $20.42 | N/A |
| Revenue Next Year | $9.87 | $2.51 |
| P/E Ratio | ★ $12.72 | $14.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.51 | $5.69 |
| 52 Week High | $92.08 | $13.83 |
| Indicator | SFBS | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.00 | 50.65 |
| Support Level | $37.51 | $13.46 |
| Resistance Level | $88.63 | $13.77 |
| Average True Range (ATR) | 0.93 | 0.04 |
| MACD | 0.88 | -0.00 |
| Stochastic Oscillator | 38.88 | 26.92 |
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.